FBRXForte Biosciences, Inc.vs its industry peers
A metric-by-metric comparison of Forte Biosciences, Inc. against Pharmaceutical Preparations — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Empresa | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FBRXEsta | $1.6B#7 | — | 8.9x#10 | 45406.7x#9 | -99.8%#10 | -95.5%#11 | -196269.4%#10 | -37.7%#11 | -45.2%#6 | — | 598.7%#2 | — |
| XNCR | $2.0B#1 | — | 4.0x#5 | 15.9x#6 | 13.7%#9 | 60.5%#6 | -141.4%#7 | -18.3%#9 | -31.5%#5 | — | 221.3%#4 | — |
| STOK | $2.0B#2 | — | 5.7x#9 | 10.7x#4 | 404.5%#3 | 92.3%#4 | -11.2%#6 | -2.0%#5 | — | — | 55.3%#10 | — |
| SNDX | $1.9B#3 | — | 123.0x#13 | 10.8x#5 | 627.8%#2 | 10.5%#9 | -158.4%#9 | -1890.2%#15 | -1205.8%#7 | — | 28.4%#11 | — |
| ETON | $1.8B#4 | — | 38.0x#12 | 22.1x#7 | 104.9%#5 | -20.4%#10 | -1.1%#5 | -9.9%#7 | -1.8%#4 | 4#2 | 246.7%#3 | — |
| SEPN | $1.8B#5 | — | 4.5x#7 | 38.1x#8 | 4174.5%#1 | 31.9%#8 | -148.6%#8 | -12.6%#8 | — | — | 165.9%#6 | — |
| DMRA | $1.7B#6 | 3.7x#2 | 3.4x#3 | — | — | -878.8%#14 | — | -40.7%#12 | — | — | 824.9%#1 | — |
| ANIP | — | 15.9x#4 | — | — | 43.8%#6 | 510.5%#2 | 12.6%#3 | 13.1%#2 | 16.9%#2 | — | -23.9%#14 | — |
| ANAB | $1.6B#8 | — | 127.6x#14 | 6.9x#3 | 157.0%#4 | 90.9%#5 | 20.4%#2 | -103.8%#14 | — | — | 147.9%#7 | — |
| TRAX | $1.6B#9 | — | 9.6x#11 | — | — | — | — | 0.0%#3 | — | — | — | — |
| LBRX | $1.6B#10 | 2.2x#1 | 4.8x#8 | — | — | 60.1%#7 | — | -7.6%#6 | — | — | 167.6%#5 | — |
| AVLN | $1.6B#11 | — | 4.0x#4 | — | — | — | — | 0.0%#3 | — | — | — | — |
| XERS | $1.6B#12 | — | — | 5.4x#2 | 43.7%#7 | 101.0%#3 | 8.5%#4 | — | 20.6%#1 | — | 8.9%#12 | — |
| BCAX | $1.6B#13 | — | 3.3x#2 | — | — | -102.9%#12 | — | -29.4%#10 | — | — | 94.8%#8 | — |
| INVA | $1.5B#14 | 5.0x#3 | 1.3x#1 | 3.8x#1 | 14.7%#8 | 1059.2%#1 | 39.8%#1 | 22.0%#1 | 14.7%#3 | 5#1 | 2.1%#13 | — |
| AVBP | $1.5B#15 | — | 4.1x#6 | — | — | -106.6%#13 | — | -45.3%#13 | — | — | 56.3%#9 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Table built 2026-09-03.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice